192 related articles for article (PubMed ID: 17343685)
21. Diagnosis and treatment of post-transplantation lymphoproliferative disorder in pediatric heart transplant patients.
Schubert S; Abdul-Khaliq H; Lehmkuhl HB; Yegitbasi M; Reinke P; Kebelmann-Betzig C; Hauptmann K; Gross-Wieltsch U; Hetzer R; Berger F
Pediatr Transplant; 2009 Feb; 13(1):54-62. PubMed ID: 18518912
[TBL] [Abstract][Full Text] [Related]
22. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
23. Risk of colorectal neoplasia in patients with solid organ transplantation.
Park HY; Chang BJ; Lim SW; Kim J; Kim JY; Chang DK; Son HJ; Rhee PL; Kim JJ; Rhee JC; Kim YH
Clin Transplant; 2012; 26(1):50-6. PubMed ID: 21272075
[TBL] [Abstract][Full Text] [Related]
24. Cancer incidence and survival in kidney transplant patients.
Navarro MD; López-Andréu M; Rodríguez-Benot A; Agüera ML; Del Castillo D; Aljama P
Transplant Proc; 2008 Nov; 40(9):2936-40. PubMed ID: 19010153
[TBL] [Abstract][Full Text] [Related]
25. Malignancies after kidney transplantation.
Rascente M; Pisani F; Barletta A; D'Angelo M; Giammaria A; Parzanese I; Rizza V; Iaria G; Famulari A
Transplant Proc; 2005; 37(6):2529-31. PubMed ID: 16182735
[TBL] [Abstract][Full Text] [Related]
26. Posttransplant malignancies in solid organ adult recipients: an analysis of the U.S. National Transplant Database.
Sampaio MS; Cho YW; Qazi Y; Bunnapradist S; Hutchinson IV; Shah T
Transplantation; 2012 Nov; 94(10):990-8. PubMed ID: 23085553
[TBL] [Abstract][Full Text] [Related]
27. Urological malignancy as a complication of renal transplantation: a report of twelve clinical cases.
Zhou M; Zhu Y; Wang L; Wang Y; Fu S; Min Z
Clin Transpl; 2006; ():395-8. PubMed ID: 18365395
[TBL] [Abstract][Full Text] [Related]
28. Urological malignancy after renal transplantation.
Besarani D; Cranston D
BJU Int; 2007 Sep; 100(3):502-5. PubMed ID: 17669141
[TBL] [Abstract][Full Text] [Related]
29. BK virus-associated nephropathy in sirolimus-treated renal transplant patients: incidence, course, and clinical outcomes.
Benavides CA; Pollard VB; Mauiyyedi S; Podder H; Knight R; Kahan BD
Transplantation; 2007 Jul; 84(1):83-8. PubMed ID: 17627242
[TBL] [Abstract][Full Text] [Related]
30. Anal dysplasia in kidney transplant recipients.
Ogilvie JW; Park IU; Downs LS; Anderson KE; Hansberger J; Madoff RD
J Am Coll Surg; 2008 Dec; 207(6):914-21. PubMed ID: 19183539
[TBL] [Abstract][Full Text] [Related]
31. Anticancer effect of sirolimus in renal allograft recipients with de novo malignancies.
Boratyńska M; Watorek E; Smolska D; Patrzałek D; Klinger M
Transplant Proc; 2007 Nov; 39(9):2736-9. PubMed ID: 18021973
[TBL] [Abstract][Full Text] [Related]
32. Sirolimus-based triple immunosupression with antithymocyte globulin induction in expanded criteria donor kidney transplantation.
Uslu A; Nart A; Taşli FA; Postaci H; Aykas A; Doğan M; Sahin T
Nephrology (Carlton); 2008 Feb; 13(1):80-6. PubMed ID: 18199109
[TBL] [Abstract][Full Text] [Related]
33. Post-transplant lymphoproliferative disease in pediatric lung transplant recipients: recent advances in monitoring.
Elidemir O; Kancherla BS; Schecter MG; McKenzie ED; Morales DL; Heinle JS; Mallory GB
Pediatr Transplant; 2009 Aug; 13(5):606-10. PubMed ID: 19017289
[TBL] [Abstract][Full Text] [Related]
34. CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation.
Maecker B; Jack T; Zimmermann M; Abdul-Khaliq H; Burdelski M; Fuchs A; Hoyer P; Koepf S; Kraemer U; Laube GF; Müller-Wiefel DE; Netz H; Pohl M; Toenshoff B; Wagner HJ; Wallot M; Welte K; Melter M; Offner G; Klein C
J Clin Oncol; 2007 Nov; 25(31):4902-8. PubMed ID: 17971586
[TBL] [Abstract][Full Text] [Related]
35. Posttransplant lymphoproliferative disorder.
Everly MJ; Bloom RD; Tsai DE; Trofe J
Ann Pharmacother; 2007 Nov; 41(11):1850-8. PubMed ID: 17940127
[TBL] [Abstract][Full Text] [Related]
36. Abdominal involvement in pediatric heart and lung transplant recipients with posttransplant lymphoproliferative disease increases the risk of mortality.
Tai CC; Curtis JL; Szmuszkovicz JR; Horn MV; Ford HR; Woo MS; Wang KS
J Pediatr Surg; 2008 Dec; 43(12):2174-7. PubMed ID: 19040929
[TBL] [Abstract][Full Text] [Related]
37. Incidence of malignancies in heart and/or lung transplant recipients: a single-institution experience.
Roithmaier S; Haydon AM; Loi S; Esmore D; Griffiths A; Bergin P; Williams TJ; Schwarz MA
J Heart Lung Transplant; 2007 Aug; 26(8):845-9. PubMed ID: 17692790
[TBL] [Abstract][Full Text] [Related]
38. Trends in invasive disease due to Candida species following heart and lung transplantation.
Schaenman JM; Rosso F; Austin JM; Baron EJ; Gamberg P; Miller J; Oyer PE; Robbins RC; Montoya JG
Transpl Infect Dis; 2009 Apr; 11(2):112-21. PubMed ID: 19254327
[TBL] [Abstract][Full Text] [Related]
39. Clinical and economic outcomes of rabbit antithymocyte globulin induction in adults who received kidney transplants from living unrelated donors and received cyclosporine-based immunosuppression.
Miller JT; Collins CD; Stuckey LJ; Luan FL; Englesbe MJ; Magee JC; Park JM
Pharmacotherapy; 2009 Oct; 29(10):1166-74. PubMed ID: 19792990
[TBL] [Abstract][Full Text] [Related]
40. Trends in adult post-kidney transplant immunosuppressive use in Australia, 1991-2005.
Chang SH; Russ GR; Chadban SJ; Campbell S; McDonald SP
Nephrology (Carlton); 2008 Apr; 13(2):171-6. PubMed ID: 18275507
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
